Voriconazole: A highly potent treatment for fungal infections

December 16, 2008

London, UK, 16 December 2008 - The effectiveness of voriconazole in combating fungal infections has been confirmed by a new study to be featured in the International Journal of Antimicrobial Agents (www.elsevier.com/locate/ijaa), published by Elsevier. Fungal infections can kill people with weakened immune systems, which can be caused by AIDS, cancer treatment or organ replacement, and the research reinforces earlier findings that this drug is a potent treatment for a wide range of these infections.

Voriconazole is an antifungal agent which has been approved for treatment of a broad range of fungal infections, including those caused by Candida species. The authors, from the United Kingdom, the United States of America and New Zealand, analyzed susceptibility data for the yeasts isolated from patients taking part in the voriconazole phase III clinical trials. The aim was to compare the effectiveness of voriconazole with other agents, by studying the yeasts' response to these antifungal agents in vitro, and also to check for resistance to voriconazole.

The researchers analyzed the effect of itraconazole, fluconazole, amphotericin B and voriconazole versus 1763 yeasts isolated from samples obtained from 472 patients. The yeast cultures obtained were predominantly Candida spp. (97.1%), although there were seven genera and 22 species of yeasts in all. The infections the patients were suffering from arose most commonly from surgery/trauma/burns (37% of patients), haematological malignancy (13%) or bacteria (11%).

The authors conclude that "Voriconazole exhibits high potency in vitro against a wide range of yeast species. It is notably more active than fluconazole in terms of both potency and spectrum, but shows similar activity to itraconazole against most yeasts." They also note that the activity of the agent in vitro may help predict the response of patients to treatment.
-end-
Notes to Editors:

The full article is: Johnson E, et al. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies, Int. J. Antimicrob. Agents (2008), doi:10.1016/j.ijantimicag.2008.05.023

For a full disclosure of authors' interests, please see the full text of the article.

For full-text copies of the article, please contact the Elsevier press office at newsroom@elsevier.com

About the International Journal of Antimicrobial Agents

The International Journal of Antimicrobial Agents (www.elsevier.com/locate/ijaa) provides comprehensive and up-to-date peer reviewed reference information on the physical, pharmacological, in vitro and clinical properties of individual antimicrobial agents (antiviral agents, antiparasitic agents, antibacterial agents, antifungal agents, immunotherapeutic agents, etc.). In addition, the journal signals new trends and developments in the field through highly authoritative review articles on antimicrobial agents, immunomodulators and immunotherapy. Special attention is given to articles providing insight into the problems of antimicrobial resistance, local as well as world-wide, both in the hospital and in the community. It is the official journal of the International Society of Chemotherapy (www.ischemo.org).

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Elsevier

Related Fungal Infections Articles from Brightsurf:

Boron nitride nanofilms for protection from bacterial and fungal infections
NUST MISIS material scientists have presented antibacterial nano-coatings based on boron nitride, which are highly effective against microbial pathogens (up to 99.99%).

New research on how fungal cells respond to stress
Numerous species of filamentous fungi are pathogens that can make people sick, especially people who are immunocompromised.

Development of novel oral formulation to treat systemic fungal infections
The Wasan Laboratory in the Faculty of Pharmaceutical Sciences at the University of British Columbia in partnership with iCo Therapeutics Inc.

Study unravels how our immune system deals with fungal and viral infections
The body's immune response to fungal infections changes when a patient is also infected by a virus, according to new research which investigated the two types of infection together for the first time.

Fungal decisions can affect climate
Research shows fungi may slow climate change by storing more carbon.

Fungal diversity and its relationship to the future of forests
Stanford researchers predict that climate change will reduce the diversity of symbiotic fungi that help trees grow.

Probiotic yeast may offer an effective treatment for drug-resistant fungal infections
Researchers at Worcester Polytechnic Institute (WPI) & the Central Food Technological Research Institute in India are studying the effect of probiotic yeast in preventing fungal infections.

'Fungal feature tracker' could accelerate mycology research
A new software tool called Fungal Feature Tracker could accelerate understanding of fungal morphology and growth.

UMD discovers new mechanism in the liver that helps prevent invasive fungal infections
An expert in intravital microscopy, Meiqing Shi, University of Maryland, is making breakthroughs in invasive fungal infections.

For hospitalized patients with fungal infections, specialists save lives
Fungal bloodstream infections are responsible for the deaths of more than 10,000 people every year.

Read More: Fungal Infections News and Fungal Infections Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.